C1710191||Difference-in-Differences Method
C2718022||Comparative Effectiveness Research
C2718022||Comparative effectiveness research
C2718022||Comparative effectiveness research
C3658316||observational studies
C1320722||administrative data
C2718022||Comparative effectiveness research
C1710191||difference-in-differences (DiD) estimation
C1710191||differences, including difference-in-differences
C0025663||method
C2718022||Comparative effectiveness research
C0242356||MarketScanÂ® Databases
C0026769||multiple sclerosis
C0026769||multiple sclerosis
C0087111||therapies
C2348484||Test Cohort
C0289884||glatiramer acetate
C0289884||glatiramer acetate
C2936279||switched
C1699926||fingolimod
C1699926||FTY
C0289884||glatiramer acetate
C0243095||no switch
C0242356||US administrative claims database
C0034980||regression
C2348484||treatment cohorts
C1710191||DiD analysis
C2348484||Test
C0206031||Logistic regression
C2936279||switching
C0289884||glatiramer acetate
C1699926||FTY
C1710191||DiD analysis
C2348484||Test Cohort
C0026769||multiple sclerosis
C0026769||multiple sclerosis
C2348484||Test Cohort
C1273937||no significant
C1710191||differences, including difference-in-differences
C0026769||multiple sclerosis
C2348484||Test Cohort
C0026769||multiple sclerosis
C1257890||population
C1710191||differences, including difference-in-differences
C1518681||treatment effects
C1257890||population
C2348484||Test
C1710191||differences, including difference-in-differences
C0599755||cohorts